Free Trial

Contineum Therapeutics 11/6/2024 Earnings Report

Contineum Therapeutics logo
$6.78 +0.32 (+4.95%)
As of 04:00 PM Eastern

Contineum Therapeutics EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Contineum Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Contineum Therapeutics Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Remove Ads

Contineum Therapeutics Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Contineum initiated with a Buy at JonesResearch
See More Contineum Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Contineum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your email.

About Contineum Therapeutics

Contineum Therapeutics (NASDAQ:CTNM), a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

View Contineum Therapeutics Profile

More Earnings Resources from MarketBeat